#USA #Los Angeles #Armata Pharmaceuticals #AP-SA02 #FDA Designations

Armata Pharmaceuticals Reports Financial Results for Q3 2026

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has recently unveiled its financial updates for the third quarter of 2026, alongside significant advancements concerning its primary product candidate, AP-SA02. This late clinical-stage biotechnology firm specializes in pathogen-specific bacteriophage therapeutics aimed at combating hard-to-treat bacterial infections, particularly those resistant to antibiotics.

Progress Towards Phase 3 Trials

During a press release on November 12, 2026, Dr. Deborah Birx, the company's CEO, emphasized the progress made in gearing up for the pivotal Phase 3 superiority study for AP-SA02. This injectable multi-phage product is being developed as an adjunct treatment for complicated Staphylococcus aureus bacteremia (SAB), targeting both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains of bacteria.

Dr. Birx pointed out that preparations have transitioned from planning to the establishment of a robust operational structure required for conducting a large-scale clinical study. Key preparations include essential manufacturing capabilities and strategic collaborations with the U.S. Food and Drug Administration (FDA) regarding the study design.

The FDA's recent granting of Breakthrough Therapy designation to AP-SA02 is a testament to its potential clinical significance and aims to expedite the review process for therapies for serious or life-threatening conditions. This designation, along with existing Fast Track and Qualified Infectious Disease Product approvals, reinforces the therapeutic promise of AP-SA02.

Significant Developments in Q3 2026

Armata continues to make strides in its clinical and operational preparations for the upcoming Phase 3 study. These include:

• - Ongoing negotiations with clinical research organizations to streamline study management.
• - Completion of several engineering runs of AP-SA02 at the company’s cGMP manufacturing site located in Los Angeles.
• - Submission of protocol revisions addressing FDA feedback received after the End-of-Phase 2 meeting.
• - Continued discussions with the FDA to finalize the study's design.

Moreover, the company reported receiving an additional $3.7 million in non-dilutive funding from the Department of War, enhancing their budget for the Phase 3 execution phase. This funding highlights the U.S. government's commitment to advancing AP-SA02, which could greatly influence patient care in the fight against antibiotic-resistant infections.

Financial Overview for Q3 2026

In terms of financial performance, Armata reported total grant and award revenues of $3.2 million for the third quarter, a substantial increase from $1.2 million reported in the same quarter from the previous year. Research and development expenses amounted to approximately $6.8 million, while general and administrative costs rose to about $3.7 million during the same period.

Armata's loss from operations was approximately $7.4 million, a slight improvement over the previous year's loss of $7.8 million. Notably, the net income for the third quarter skyrocketed to $54.9 million, attributed mainly to a significant gain of $69.6 million from changes in the fair value of a convertible loan.

As of September 30, 2026, Armata held nearly $18.3 million in unrestricted cash, which is a considerable increase from $8.7 million reported at the end of the previous year. This increase indicates solid financial grounding and the company’s capacity to pursue its development programs going forward.

Looking Ahead

With the FDA’s continued collaboration, and the planned launch of the Phase 3 clinical trial in the latter half of 2026, Armata Pharmaceuticals stands poised to potentially revolutionize the treatment of severe bacterial infections through its innovative phage therapy technology. Their commitment to developing effective solutions against antibiotic-resistant infections exemplifies a crucial advancement in the field of biotechnology.

In summary, the presented financial results and corporate updates position Armata's AP-SA02 as a key player in addressing the urgent healthcare need for effective treatments against resistant bacterial strains. The company's operational and financial strategies signal its readiness to face upcoming challenges in the clinical development landscape.